Literature DB >> 21647835

[Principles of cholesteatoma surgery].

T Stark1, A Gurr, H Sudhoff.   

Abstract

As a potentially life-threatening disease, cholesteatoma of the petrous bone generally requires a surgical approach. Surgery aims to produce an ear that is easy to care for and is free of recurrent or residual cholesteatoma. Hearing improvement is of secondary importance. Nevertheless the sound conduction system is generally reconstructed as a single-stage procedure. There are various possible methods of dealing with a cholesteatoma: (i) preserving or reconstructing the posterior meatal wall with an aerated mastoid (closed technique) or obliteration of the mastoid completely or partially after removal of the posterior wall (closed technique); and (ii) leaving the cavity open for inspection (open technique). In our opinion any technique where the mastoid is not open for inspection should be called a closed technique. Both techniques have their specific advantages and disadvantages.

Entities:  

Mesh:

Year:  2011        PMID: 21647835     DOI: 10.1007/s00106-011-2265-4

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  22 in total

1.  Facial nerve monitoring in middle ear and mastoid surgery.

Authors:  R S Noss; A K Lalwani; C D Yingling
Journal:  Laryngoscope       Date:  2001-05       Impact factor: 3.325

2.  Reconstruction of the middle ear with hydroxylapatite implants: long-term results.

Authors:  J J Grote
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1990-02

3.  [The relevance of anatomical courses in ENT-education].

Authors:  A Gurr; S Hansen; A Minovi; G Probst; S Dazert
Journal:  Laryngorhinootologie       Date:  2009-12-21       Impact factor: 1.057

4.  The operation and death of Henry Schliemann.

Authors:  F H McGovern
Journal:  Laryngoscope       Date:  1977-10       Impact factor: 3.325

5.  [The "old radical" surgery. History and development of surgery of the mastoid].

Authors:  D Plester
Journal:  Laryngol Rhinol Otol (Stuttg)       Date:  1985-05

6.  Encephalopathy with seizures after use of aluminium-containing bone cement.

Authors:  P Hantson; P Mahieu; M Gersdorff; C J Sindic; R Lauwerys
Journal:  Lancet       Date:  1994-12-10       Impact factor: 79.321

7.  The metaplastic and congenital origin of cholesteatoma.

Authors:  J Sadé; A Babiacki; G Pinkus
Journal:  Acta Otolaryngol       Date:  1983 Jul-Aug       Impact factor: 1.494

8.  The common pig: a possible model for teaching ear surgery.

Authors:  André Gurr; K Kevenhörster; T Stark; M Pearson; S Dazert
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-12       Impact factor: 2.503

9.  Post-traumatic cholesteatoma.

Authors:  K X McKennan; R A Chole
Journal:  Laryngoscope       Date:  1989-08       Impact factor: 3.325

10.  Treatment of cholesteatoma.

Authors:  J Sadé
Journal:  Am J Otol       Date:  1987-11
View more
  4 in total

1.  Hearing outcomes following primary malleostapedial rotation ossiculoplasty in patients undergoing modified radical mastoidectomy.

Authors:  R G Kanegaonkar; M Whittaker; A Najuko-Mafemera
Journal:  Ann R Coll Surg Engl       Date:  2014-09       Impact factor: 1.891

Review 2.  Infectious causes of cholesteatoma and treatment of infected ossicles prior to reimplantation by hydrostatic high-pressure inactivation.

Authors:  Wycliffe Omurwa Masanta; Rebecca Hinz; Andreas Erich Zautner
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

3.  Cold atmospheric plasma for local infection control and subsequent pain reduction in a patient with chronic post-operative ear infection.

Authors:  G Isbary; T Shimizu; J L Zimmermann; H M Thomas; G E Morfill; W Stolz
Journal:  New Microbes New Infect       Date:  2013-12-04

4.  Identification of risk factors for residual cholesteatoma in children and adults: a retrospective study on 110 cases of revision surgery.

Authors:  Veronika Volgger; Göran Lindeskog; Eike Krause; Florian Schrötzlmair
Journal:  Braz J Otorhinolaryngol       Date:  2018-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.